Vascular Cures welcomes Dr. Aruna Pradhan, MD, MPH to our Scientific Advisory Board! Dr. Pradhan is a cardiologist, epidemiologist and clinical trialist at the Brigham and Women’s Hospital and is actively involved in the design, conduct, and analysis of a number of large-scale observational studies and randomized clinical trials of cardiovascular disease (CVD), peripheral artery disease (PAD), and type 2 diabetes (T2D). As Scientific Director of the Preventive Medicine Cohorts Biorepository, she has technical expertise in collection, long-term storage, quality control and management of biomarker studies. She has served as the Principal Investigator (PI) of the LANCET trial (a randomized clinical trial of insulin glargine for CRP reduction in early T2D) and several NIH R01s including HL103742 evaluating biomarkers of statin-induced diabetes in the JUPITER trial, HL122158 evaluating the effect of low dose methotrexate on PAD incidence within the Cardiovascular Inflammation Reduction Trial (CIRT) and DK088078 evaluating incident diabetes in the Vitamin D and Omega-3 Trial (VITAL). In addition, she is Co-PI of the recently initiated industry-sponsored Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Diabetic Patients (PROMINENT) trial, which will evaluate the selective peroxisome proliferator activator receptor–alpha modulator (SPPARM-α) for CVD event reduction in T2D. She actively participates in teaching and mentoring of students and trainees within the Division of Preventive Medicine, and spends one day a week practicing general cardiology and echocardiography at the VA Boston Medical Center.